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Abstract[  
A study was conducted to compare the performance of the OnLine 
and OnTrak immunoassays for benzodiazepines with gas 
chromatographic-mass pectrometric (GC-MS) analysis in 
detecting flunitrazepam (FNP) and its metabolites in human urine. 
Urine was collected over a 72-h period from six individuals 
(four male and two female) who had taken a single oral dose of 
either 1 or 4 mg of FNP. The OnTrak assay was run at a 100-ng/mL 
cutoff of nordiazepam (NDP), and the OnLine assay was run with a 
standard curve from zero to 200 ng/mL of NDP with and without 
~-glucuronidase treatment. Each sample was analyzed by GC-MS 
using FNP, 7-amino-FNP, 3-hydroxy-FNP, desmethyI-FNP, 7-amino- 
3-hydroxy-FNP, and desmethyl-3-hydroxy-FNP as standards with 
13-glucuronidase treatment. The specimens from the l-rag dose did 
not yield a positive result byimmunoassay over the 72-h collection 
period. Specimens from the 4-rag dose did yield positive r sults in 
both immunoassays. The time of the first positive result ranged 
from 4 to 12 h, and the time to the last positive result ranged from 
18 to 60 h. Treatment of the samples with ~-glucuronidase 
increased the OnLine values between 20 and 60%, but it did not 
appreciably increase the detection time. GC-MS analysis howed 
no detectable levels of FNP, 3-hydroxy-FNP, desmethyI-FNP, 
7-amino-3-hydroxy.FNP, and desmethyl-3-hydroxy-FNP. However, 
all samples collected past time zero showed detectable levels of
7-amino-FNP (> 2 ng/mL) with peak concentrations at 12-36 h. 
The peak levels of 7-amino-FNP by GC-MS paralleled the peak 
levels of the immunoassay response. The amount of 7-amino-FNP 
metabolite quantitated by GC-MS, however, accounted for only 
15-20% of the total immunoassay crossreactive FNP metabolites. 
Introduction 
Flunitrazepam (FNP) is a prescription sleeping aid that is one 
of a widely used class of prescription medications known as 
benzodiazepines (1). The drug is sold under the trade name 
Rohypnol and is distributed in 64 countries throughout the 
* Author to whom correspondence should be addressed. 
world. It is one of the more commonly used benzodiazepines in 
certain countries, and its abuse is evident in the intravenous 
drug population (2). The drug is not sold in the United States, 
but there have been increasing reports that the drug is being 
illegally diverted into the country and illicitly sold (3). 
Chromatographic methods such as gas chromatography and 
liquid chromatography were developed to det rmine FNP and 
its metabolites in various body fluids (1,4). However, the 
detection of flunitrazepam in urine has been of concern to 
toxicologists for several ye rs (5-7). Although commercially 
available assays show some cmssreactivity to FNP, very little of 
the parent drug appears in urine (8). It is extensively metabo- 
lized by reduction of the nitro group followed by acetylation, 
hydroxylation f the 3-position followed by glucuronidation, 
and N-demethylation (Figure 1). In addition to the compli- 
rated metabolism ofFNP, the lower therapeutic doses of this 
compound compared with the older generation f benzodi- 
azepines make its detection in uri e difficult. 
Although a controlled study was conducted to determine the 
excretion pattern of FNP by immunoassays (7), there are no 
available studies that compare the excretion patterns of FNP 
with immunoassays followed by gas chromatographic-mass 
spectrometric (GC-MS) analysis. In this study, we compare the 
excretion profiles of six individuals who have taken either a 1- or 
4-rag dose of FNP by the OnTrak and OnLine immunoassays 
(Roche Diagnostic Systems, Somerville, N J) followed by GC--MS. 
Experimental 
Materials 
FI~, 7-amino-FNP, 3-hydroxy-FNP, desmethyl-FNP, 7-amino- 
3-hydroxy-FNP, and desmethyl-3-hydroxy-FNP wereall supplied 
by Roche Laboratories (Nutley, N J). [3-Glucuronidase ([3-glu- 
curonide glucuronosohydrolase, EC 3.2.1.31) was purchased 
from Boehringer Mannheim (Indianapolis, IN). The Cobas 
Integra was provided by Roche Diagnostic Systems. 
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Biological samples 
This study was approved by the Ethics Committee of the 
Faculty of Medicine from the University of Bern. All subjects 
that participated in the study were volunteers and supplied 
informed consent. Four healthy male subjects (30-47 years of 
age, 59-87 kg in weight) and two healthy female subjects 
(25--40 years ofage, 55-72 kg in weight) participated in the 
study. A single oral dose of 1 or 4 mg of FNP was ingested in the 
evening by each subject. Urine sp cimens were collected, and 
the volume was measured at the time of FNP administration 
(time 0 h) and at 2, 4, 8, 12, 18, 24, 30, 36, 48, 60, and 72 h after 
drug ingestion. Specimens were collected in polypropylene 
bottles without additives and immediately refrigerated. All spec- 
imens from the study were frozen at -24~ within 12 h of 
collection. 
Immunological assays 
Benzodiazepine kits for the OnTrak and OnLine assays were 
obtained from Roche Diagnostic Systems. The OnTrak assay is 
a single test qualitative assay with a 100-ng/mL cutoff using 
nordiazepam as a standard. The OnLine assay was run on the 
Cobas Integra in the quantitative mode using a four-point linear 
interpolation standard curve based onnordiazepam (0, 50, 100, 
and 200 ng/mL) calibrators. TheOnLine assay was run in two 
different modes according to manufacturer's in tructions. One 
mode used the standard assay without pretreatment of the 
urine sample. The second mode used a [~-glucuronidase pre- 
treatment step that is incorporated directly on the instrument. 
The [3-glucuronidase (0.4 units) is incubated with the sample, 
sample diluent, and antibody for 2.6 rain before the instru- NO 
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Figure 1. Flunitrazepam etabolism in humans. 
ment adds the start reagent. The clinical limit ofdetection for 
both modes of the OnLine assays was determined to be 
26 ng/mL. The intra-assay coefficient of variation (CV) for both 
assays at the 50 ng/mL level averaged 7.1% (n = 20), and the 
interassay CV at the 50 ng/mL level averaged 7.6% (n = 200). 
FNP-3-Glucuronide 
O 
lip H=N~ N~OH 
7-NH2-3-OH-FNP 
GC-MS analysis 
Urine samples were hydrolyzed with [3-glucuronidase and 
extracted with chloroform-isopropanol (9:1). For the best 
chromatographic separation and the least interference, 
trimethylsilyl (TMS) derivatization was chosen for 7-amino- 
FNP, 3-hydroxy-FNP, and desmethyl-FNP (group I). Tertiary- 
butyldimethylsilyl trifluoroacetamide (TBDMS) derivatization 
was chosen for 7-amino-3-hydroxy-FNP and desmethyl-3- 
hydroxy-FNP (group II). Even though flunitrazepam itself was 
not derivatized by either method, itwas analyzed with group I
compounds. Oxazepam-d5 was used as the internal standard. 
The identification and quantitation f the analytes were per- 
formed using selected ion monitoring (SIM). The ions selected 
for this purpose were chosen from full scan mass pectral ana- 
lysis of 5 I~g/mL standard of each analyte. Two ions were chosen 
to monitor the presence or absence of each analyte. A linear 
calibration curve of 10, 25, 50, 150, and 300 ng/mL was used for 
7-amino-FNP and 7-amino-3-hydroxy-FNP; a calibration curve
of 50, 150, and 300 ng/rnL was used for the other analytes. A 
negative control was included along with an unextracted stan- 
dard to calculate the extraction recovery. Specimens a dcon- 
trols had to have retention times and ion ratios within -i-_ 2% 
and 20%, respectively, of the standards. 
The following procedure was used: internal standard 
(30 I~L) containing 40 IJg/mL of oxazepam-d5 
was added to 4 mL urine in a 15-mL cen- 
trifuge tube. Acetate buffer (1.0 mL, 1.1M, 
pH 5.2) was added to each tube. One hundred 
microliters of glusulase (DuPont, containing 
10,000 units [3-glucuronidase/mL and ap- 
proximately 9000 units/mL sulfatase) was 
added to each tube. The tubes were capped 
loosely and vortex mixed briefly, and then 
placed in a 37~ oven for 4 h. After hydro- 
lysis, the tubes were removed from the oven 
and allowed to cool to room temperature. 
One milliliter of phosphate buffer (40%, pH 
9.0) was added toeach tube. Eight milliliters 
of chloroform-isopropanol (9:1) was added to 
each tube. The tubes were then shaken for 
2 rain. If necessary, the tubes were centri- 
fuged to break the emulsion. The aqueous 
layer was discarded, and the organic layer 
was shaken with 1 mL distilled water. The
aqueous layer was again discarded. The 
organic layer was poured into 13 • 100-mm 
tubes and evaporated under nit ogen at 50~ 
to a volume of approximately 1 mL. This 
volume was transferred to GC vials, and the 
solvent was evaporated under nitrogen. 
For group I analytes, 100 IJL BSTFA (con- 
taining 1% TMCS) was added, and the vials 
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were capped and placed in a 70~ oven for 30 rain. The vials 
were removed from the oven and cooled to room temperature. 
The samples were then transferred into a GC insert and capped. 
The samples (2 pL) were injected onto the GC-MS. For group 
II analytes, 75 IJL of MTBSTFA (N-tert-butyldimethylsilyl)-N- 
methyl trifluoroacetamide with 1% TBDMSC1 was added in- 
stead of BSTFA. The derivatization time and temperature w re 
the same as those for BSTFA. A GC-vial insert was also used. 
Two microliters of samples were also injected on GC-MS. 
A Hewlett Packard 5890 GC with an HP 5970 mass selective 
detector and a Chemstation data system were used inelectron 
ionization mode (70 eV) with 8IM. To analyze group I analytes, 
a 10-m x 0.18-ram (0.4-pro film thickness) DB-1 column (J&W 
Scientific, Folsom, CA) was used (Table I). The temperature 
was programmed at 180~ (held for 0.5 min) to 280 ~ at 30~ 
(held for 6 rain) and to 300~ at 30~ (held for 1.5 rain). 
The samples (2 pL) were injected in the splitless mode with the 
valve closed for 0.2 rain. The splitless injector emperature was 
250~ and the detector temperature was 280~ The helium 
carrier flow was 43 cm/s. 
To analyze group II compounds (Table I), a 25-m x 0.2-ram 
(0.33-pro film thickness) DB-5 MS column (J&W Scientific) was 
operated under similar conditions, but the temperature was 
programmed as follows: 220~ (held for 0.2 rain) to 280~ at 
30~ (held for 12.5 rain). 
Results 
The irnmunoassay data shows that with the l-rag dose, the 
urine concentration was below the clinical imit of detection in 
all three individuals with the unmodified OnLine assay over the 
72-h period. Using the ~-glucuronidase pretreatment, several 
samples howed low concentrations of crossreactive benzodi- 
azepines with the OnLine assay. The values ranged between 
34 and 43 ng/mL and were found between 12 and 30 h (Table 
II). The OnTrak assay with a 100-ng/mL cutoff gave negative 
results with all the 1-mg dose subjects throughout the 72-h 
Table I. Retention Times and Ions Monitored for Group I 
and Group II Analytes 
Compounds Retention time (min) Ions 
Group I (rMS derivatives) on DB-1 column 
Oxazepam-ds* 4.196 420, 434 (QI) t 
DesmethyI-FNP 4.575 352, 371 (QI) 
Flunitrazepam (FNP) 5.103 286, 312 (QI) 
7-Amino-FNP 5.548 327, 355 (QI) 
3-Hydroxy-FNP 5.803 386, 372 (QI) 
Group II (TBDMS derivatives) on DB-5 column 
Oxazepam-ds* 7.708 
Desmethyl-3-Hydroxy-FNP 11.661 
7-Amino-3-Hydroxy-FNP 12.809 
* Internal standard. 
"1" Quantitation ion. 
519,462 (QI) t 
487,486 (QI) 
282,356 (QI) 
collection period. 
With the 1-mg dose, the GC-MS analysis was able to detect 
the presence ofthe 7-amino-FNP metabolite at concentrations 
ranging from 2 to 58 ng/mL over the entire 72-h period with 
the highest concentrations appearing between 12 and 60 h 
(Table II). The parent drug (FNP) and the four other metabolites 
were not detected by GC-MS. 
The immunoassay results with the 4-mg dose showed levels 
of crossreactive benzodiazepines substantially higher than those 
of the l-rag dose. The unmodified OnLine assay registered 
levels ranging from 30 to 172 ng/mL between 8 and 60 h. The 
modified assay using [3-glucuronidase gave values that were 
20 to 80% higher than the unmodified assay (Table III). The On- 
Trak assay gave positive results for these samples between 
8 and 60 h. Figure 2 shows the excretion profiles of the three 
4-rag dose subjects with and without [3-glucuronidase tr at- 
ment. Normalizing the values for creatinine concentrations 
did not change the excretion profile considerably. 
The GC-MS values for the 4-rag dose subjects were also sub- 
stantially higher than for the l-rag dose subjects. Concentra- 
tions of 7-amino-FNP ranged from 2 to 118 ng/mL over the 
72-h period with maximum levels appearing between 8 and60 h 
(Table III). The excretion profiles for all three 4-rag dose sub- 
jects using the 7-amino-FNP GC-MS concentrations are shown 
Table II. Urinary Excretion of Flunitrazepam after a 1-mg 
Dose in Three Individuals 
Ontine-Cobas Integra OnTrak 
Patient Time after GC-MS 0.0 U Enz. 0.4 U Enz. 100-ng/mL 
sample ingestion (h) 7-AFNP conc.* conc.* cutoff 
AI 0 0 <0 <0 - 
A2 2 3 <0 <0 - 
A3 12 58 19 43 - /+ 
A4 18 12 <0 <0 - 
A5 24 24 2 7 - 
A6 30 23 25 34 - 
A7 36 19 4 9 - 
A8 48 7 12 16 - 
A9 60 8 <0 <0 - 
A10 72 2 <0 <0 - 
811 0 0 <0 <0 - 
812 8 8 <0 <0 - 
813 12 7 <0 <0 - 
814 18 23 7 13 - 
815 30 27 31 42 - 
816 36 11 17 22 - 
817 48 14 <0 <0 - 
818 60 14 4 6 - 
B19 72 9 <0 <0 - 
C20 0 0 <0 <0 - 
C21 18 9 <0 <0 - 
C22 24 7 <0 <0 - 
C23 30 6 <0 <0 - 
C24 36 6 <0 <0 - 
C25 48 13 <0 <0 - 
C26 60 24 2 8 - 
C27 72 5 <0 <0 - 
* ng/mL 
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in Figure 3. FNP, desmethyl-FNP, desmethyl-3-hydroxy-FNP, 
and 7-amino-3-hydroxy-FNP were not detected in any of the 
samples. The 3-hydroxy-FNP metabolite was detected in one 
individual between 8 and 24 h at concentrations between 60 and 
93 ng/mL. It was also detected in the 12-h void of another 
individual at a concentration of68 ng/mL. 
Conclusion 
The immunoassay data show that 1-mg doses ofFNP were 
difficult o detect in urine at any level. The use of [~-glucuroni- 
dase in the assay increased the sensitivity, but the detection 
window as very narrow, and the levels remained below 50 ng/mL. 
The immunoassay levels in urine samples from individuals that 
have taken a 4-rag dose were substantially higher and could 
readily be detected atconcentrations above 50 ng/mL. The use 
of [~-glucuronidase in the immunoassay converted the glu- 
Table III. Urinary Excretion of Flunitrazepam after a 
4-mg Dose in Three Individuals 
OnLine-Cobas Integra OnTrak 
Patient Time after GC-MS 0.0 U Enz. 0.4 U Enz. 100-ng/mt 
sample ingestion (h) 7-AFNP conc.* conc.* cutoff 
D40 0 0 <0 <0 - 
D41 8 71 30 74 + 
D42 12 42 86 154 + + 
D43 18 3 45 79 - 
D44 24 68 107 154 + 
D45 30 67 97 124 + 
D46 36 13 1 9 - 
D47 48 34 0 9 - 
D48 60 2 <0 <0 - 
D49 72 2 <0 <0 - 
E50 0 0 <0 <0 - 
E51 2 16 <0 <0 - 
E52 4 44 21 41 + 
E53 8 80 108 169 + 
E54 12 118 178 183 + 
E55 18 104 172 >200 + 
E56 24 63 111 136 + 
E57 30 67 124 165 + 
E58 36 81 132 170 + 
E59 48 65 48 74 + 
E60 60 59 59 93 + 
E61 72 23 4 10 - 
F62 0 0 1 1 - 
F63 12 110 124 167 + 
F64 18 46 9 27 - 
F65 24 55 20 40 - 
F66 30 35 39 66 + 
F67 36 84 139 182 + 
F68 48 25 0 7 - 
F69 60 28 29 39 + 
F70 72 t8 8 7 - 
* ng/mL. 
t" Bold numbers indicate r sults that are greater than or equal to the normal urine 
immunoassay cutoff: of 100 n~mL. 
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curonidated benzodiazepine metabolite, with low crossreactivity, 
into an unconjugated molecule that has higher crossreactivity. 
The treatment increased the immunoassay values by 20 to 80% 
(Tables II and III). The use of [3-glucuronidase tr atment to
increase benzodiazepine immunoassay sensitivity isnot a new 
method and has been previously reported (5,7,9,10). 
The On1Yak assay, which has a cutoff of 100 ng/mL, identified 
all the OnLine samples that had values above 30 ng/mL as pos- 
itive. The reason for thisincreased sensitivity could be explained 
by the difference in the OnTrak and OnLine antibody cross- 
reactivities. The OnTrak antibody had a higher crossreactivity 
to FNP, 7-amino-FNP, 7-arnino-3-hydroxy-FNP, and7-amino-1- 
desmethyl-FNP than did the OnLine antibody (Table IV). This 
difference was sufficient to increase the assay sensitivity without 
the need for ~-glucuronidase tr atment. 
The GC-MS results indicate that he 7-arnino-FNP metabolite 
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Figure 2. Urinary excretion profile (nordiazepam equivalents)of subjects 
D, E, and F after a 4-mg dose using OnLine with (/k) and without ([2) 
[3-glucuronidase treatment. 
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Figure 3. Urinary excretion profile of 7-amino-FNP of individuals D (I"3), E (A), and F (O) after a 4-rag 
dose using GC-MS with ~-glucuronidase hydrolysis. 
Table IV. Cross-Reactivity of FNP and its Metabolites in 
the OnLine and OnTrak Immunoassays Relative to 
100 ng/mL of Nordiazepam 
Compounds OnLine OnTrak 
Flunitrazepam 55% 80% 
7-Amino-flunitrazepam 30% 80% 
3-Hydroxy-flu nitrazepam 26% 27% 
Desmethyl-flu nitrazepam 59% 59% 
7-Amino-3-hydroxy-flunitrazepam 11% 20% 
7-Amino-1 -desmethyl-flu nitrazepam 10% 50% 
is the most abundant metabolite out of the five metabolites 
studied. Out of the other four metabolites, only the 3-hydroxy- 
FNP metabolite was observed and then only in a few samples. 
The values of the 7-amino-FNP metabolite paralleled thoseof 
the immunoassay values. Using GC-MS with a low limit of de- 
tection (2 ng/mL) allowed for confirmation of 7-amino-FNP 
up to 72 h with doses as low as I rag. 
The OnLine immunoassay values were substantially higher 
than the GC-M8 values for 7-amino-FNP. Because th OnLine 
antibody had 30% crossreactivity to the 7-amino-FNP metabo- 
lite, it indicated that there was a considerable amount of 
metabolite that was not being identified. The 7-amino-FNP 
metabolite accounts for only 15-20% of the total crossreactive 
benzodiazepine metabolites detected by the immunoassay. An 
alternative GC-MS procedure in which the metabolites were 
hydrolyzed to the corresponding benzophenone derivatives was 
developed (11). This procedure gave values that better 
accounted for the total immuno-crossreactive benzodiazepines 
found in the clinical samples. 
The use of [3-glucuronidase treatment in the detection of flu- 
nitrazepam use was best seen in cases where lower doses of the 
drug are used. This could be seen in cases uch 
as date rape in which a limited number of 
tablets were added to a victim's drink. The im- 
munoassay values of these samples were gen- 
erally low, and enzyme treatment increased the 
window of detection (unpublished data). In 
driving-under-the-influence (DUI) cases, the 
levels of FNP metabolites were generally far 
higher (12), and the use of ~-glucuronidase 
treatment was less critical. In summary, the 
use of I~-glucuronidase tr atment in im- 
munoassays increased th  window of detection 
for all uses of the drug and especially aided in 
the detection ofFNP use when low amounts of 
the drug were taken. 
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